Following the release of its second-quarter results report, which surpassed sales projections, Bio-Rad Laboratories, Inc. (NYSE: BIO) saw a significant increase in share price last Friday. BIO’s shares closed at $284.60, up 17.63% for the day. Through careful cost control and rigorous execution, the firm saw strong increase in both revenue and operating profit during the quarter that ended on June 30, 2025.
Portfolio Expansion for Droplet Digital PCR
Bio-Rad finalized the acquisition of Stilla Technologies, a manufacturer of droplet digital PCR (ddPCR) devices, concurrently with its profits. With the purchase, Bio-Rad’s product range is expanded to include the QX700 series of ddPCR equipment, which enhances the company’s recently introduced QX Continuum system.
By combining these platforms with the business’s current QX200 and QX600 systems, a large range of over 400,000 assays for diagnostics and research is created. Targeting important domains including cancer, infectious diseases, and genetic research, the enlarged product line offers high-precision measurement, sophisticated multiplexing, and optimized processes.
Excellent Sales Results in All Segments
Total net sales for the second quarter of 2025 were $651.6 million, up 2.1% from $638.5 million in the same quarter of 2024. Sales increased 1.0% on a currency-neutral basis, mostly due to increased demand for goods used in process chromatography.
While the Clinical Diagnostics section provided $388.8 million, which was almost unchanged from the previous year, the Life Science segment generated $262.8 million, up 4.9% year over year.
Profits from Investments Increase Profitability
A shift in the fair market value of the company’s stake in Sartorius AG was a major contributor to its profitability. In contrast to a net loss of $2,165.5) million, or $(76.26) per diluted share, in the same quarter of 2024, this adjustment helped to generate a net gain of $317.8 million, or $11.67 per diluted share.
Net income for the quarter was $71.0 million, or $2.61 per diluted share, on a non-GAAP basis, as opposed to $88.3 million, or $3.11 per share, in the same period last year.
Bio-Rad strengthened its position as a global leader in life science and diagnostics with solid financial results, well-timed acquisitions, and an enlarged ddPCR product.
